Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday

Fate Therapeutics (NASDAQ:FATE) will likely be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $1.4910 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). Fate Therapeutics had a negative net margin of 2,051.08% and a negative return on equity of 55.02%. The business had revenue of $1.37 million during the quarter, compared to analyst estimates of $1.20 million. On average, analysts expect Fate Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fate Therapeutics Stock Performance

Fate Therapeutics stock traded up $0.39 during mid-day trading on Tuesday, hitting $2.19. 6,272,140 shares of the company traded hands, compared to its average volume of 1,724,621. Fate Therapeutics has a one year low of $0.91 and a one year high of $2.25. The stock has a market cap of $254.08 million, a price-to-earnings ratio of -1.89 and a beta of 2.13. The stock has a fifty day moving average price of $1.29 and a 200-day moving average price of $1.20.

Analyst Ratings Changes

Several equities research analysts have issued reports on FATE shares. Weiss Ratings lowered shares of Fate Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. HC Wainwright boosted their price objective on shares of Fate Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Monday. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.50.

Institutional Investors Weigh In On Fate Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FATE. Invesco Ltd. grew its position in shares of Fate Therapeutics by 20.4% in the 4th quarter. Invesco Ltd. now owns 379,025 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 64,200 shares during the period. Man Group plc grew its position in shares of Fate Therapeutics by 18.9% in the 4th quarter. Man Group plc now owns 261,172 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 41,514 shares during the period. Bank of America Corp DE grew its position in shares of Fate Therapeutics by 20.0% in the 3rd quarter. Bank of America Corp DE now owns 146,553 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 24,423 shares during the period. Wells Fargo & Company MN grew its position in shares of Fate Therapeutics by 28.7% in the 4th quarter. Wells Fargo & Company MN now owns 172,283 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 38,444 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in shares of Fate Therapeutics by 35.0% in the 4th quarter. Bridgeway Capital Management LLC now owns 135,000 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 35,000 shares during the period. 97.54% of the stock is currently owned by institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.